VYNE Therapeutics (VYNE) News Today → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free VYNE Stock Alerts $2.50 +0.03 (+1.21%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineVYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth Plansfinance.yahoo.com - April 13 at 8:27 AMVYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conferencefinance.yahoo.com - March 19 at 9:08 AMVYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conferenceglobenewswire.com - March 19 at 8:00 AMWall Street Breakfast Podcast: NYCB Gets $1B Investment Boostseekingalpha.com - March 7 at 8:21 AMVYNE Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lagfinance.yahoo.com - March 3 at 8:59 AMBuy Rating on VYNE Therapeutics: Strong Financials and Promising Clinical Developmentsmarkets.businessinsider.com - February 29 at 7:00 PMVYNE Therapeutics Inc.: VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Updatefinanznachrichten.de - February 29 at 10:04 AMVYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Updateglobenewswire.com - February 29 at 8:00 AMVYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposiumfinance.yahoo.com - February 27 at 8:06 AMVYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposiumglobenewswire.com - February 27 at 8:00 AMVYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conferencefinance.yahoo.com - February 21 at 8:16 AMVYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conferenceglobenewswire.com - February 21 at 8:00 AMFavourable Signals For VYNE Therapeutics: Numerous Insiders Acquired Stockfinance.yahoo.com - February 2 at 7:18 AMBuy Rating for VYNE Therapeutics Backed by Promising Vitiligo Drug Trial Resultsmarkets.businessinsider.com - January 10 at 4:27 PMVYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directorsfinance.yahoo.com - January 3 at 9:29 AMVYNE Therapeutics says director Lepore buys 13K shares in comsn.com - November 20 at 3:25 PMCormorant Asset Management, LP Acquires New Stake in VYNE Therapeutics Incfinance.yahoo.com - November 14 at 5:53 PMVYNE Therapeutics files to sell 36.27M shares for holdersmsn.com - November 13 at 5:35 PMVYNE Therapeutics Inc.: VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updatefinanznachrichten.de - November 13 at 12:34 PMRecap: VYNE Therapeutics Q3 Earningsbenzinga.com - November 13 at 9:14 AMVYNE Therapeutics GAAP EPS of -$2.01, revenue of $0.1Mmsn.com - November 13 at 9:14 AMVYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - November 13 at 9:14 AMPromising Vitiligo Treatment Trials and Increased Diagnosis Rates Boost VYNE Therapeutics’ Buy Rating: An Overviewmarkets.businessinsider.com - November 12 at 8:40 AMVYNE Therapeutics secures $88M PIPE deal to advance clinical programsinvesting.com - November 9 at 9:11 AMVYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023finance.yahoo.com - November 7 at 9:26 AMCellectis, VYNE Therapeutics among healthcare moversmsn.com - November 3 at 10:44 AMVYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Millionfinance.yahoo.com - November 1 at 8:44 PMVYNE Therapeutics (VYNE) Price Target Increased by 17.86% to 16.83msn.com - November 1 at 3:44 PMNasdaq Gains Over 1%; McDonald's Reports Upbeat Earningsbenzinga.com - October 31 at 5:53 PMWall Street Set to Open Higher Monday as Investors Parse Earnings, Await Fed Meetingmsn.com - October 30 at 8:56 PMDow Surges Over 500 Points; Western Digital Announces Plan To Split Into Two Companiesbenzinga.com - October 30 at 3:56 PMCrude Oil Falls Over 3%; Miromatrix Medical Shares Spike Higherbenzinga.com - October 30 at 2:42 PMVYNE Therapeutics Shares Rise 51% After Positive Data for Vitiligo Treatmentmarketwatch.com - October 30 at 2:42 PMWhy Vyne Therapeutics Stock Is Climbingbenzinga.com - October 30 at 2:42 PMJKS, CHRS and BMRA are among pre market gainersmsn.com - October 30 at 9:00 AMVYNE Therapeutics Announces Positive Pre-clinical Data For Its VYN202markets.businessinsider.com - October 30 at 9:00 AMVYNE Therapeutics Sees Positive Data for VYN201, VYN202marketwatch.com - October 30 at 8:20 AMVYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligofinance.yahoo.com - October 30 at 8:20 AMVYNE Therapeutics Announces Private Placement of $88 Millionfinance.yahoo.com - October 30 at 8:20 AMVYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202finance.yahoo.com - October 30 at 8:20 AMVYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - September 6 at 9:44 AMHow Much Upside is Left in VYNE Therapeutics Inc. (VYNE)? Wall Street Analysts Think 626.2%msn.com - August 17 at 3:35 PMVYNE Therapeutics Non-GAAP EPS of -$2.82, revenue of $0.14M beats by $0.09Mmsn.com - August 14 at 2:03 PMH.C. Wainwright Reaffirms Their Buy Rating on VYNE Therapeutics (VYNE)markets.businessinsider.com - August 14 at 2:03 PMOptiNose (OPTN) Q2 Earnings and Revenues Top Estimatesmsn.com - August 10 at 9:52 AMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (LLY), UnitedHealth (UNH) and Caliber Imaging & Diagnostic (OtherLCDX)markets.businessinsider.com - July 19 at 12:46 AMVYNE Therapeutics (NASDAQ: VYNE)fool.com - June 6 at 12:15 PMVYNE Therapeutics to Attend BIO International Conventionfinance.yahoo.com - May 18 at 10:24 AMCan VYNE Therapeutics Inc. (VYNE) Climb 415.04% to Reach the Level Wall Street Analysts Expect?msn.com - May 17 at 1:04 PMCantor Fitzgerald Maintains VYNE Therapeutics (VYNE) Overweight Recommendationmsn.com - May 13 at 7:31 AM Get VYNE Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter. Email Address The Next Step of Their Control Is Here … (Ad)Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you. 4 simple steps to protect your privacy and money before it’s too late. VYNE Media Mentions By Week VYNE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VYNE News Sentiment▼0.000.32▲Average Medical News Sentiment VYNE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VYNE Articles This Week▼01▲VYNE Articles Average Week Get VYNE Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CASI News Today THTX News Today ACXP News Today VIRX News Today IPA News Today FBIO News Today NRXP News Today DARE News Today XLO News Today APRE News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VYNE) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJim Cramer’s “The Biggest Drug Ever”Behind the MarketsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
